Utilization of Microfluidic Droplet-Based Methods in Diagnosis and Treatment Methods of Hepatocellular Carcinoma: A Review.

Akvilė Zajanckauskaite, Miah Lingelbach, Dovilė Juozapaitė, Algirdas Utkus, Greta Rukšnaitytė, Goda Jonuškienė, Aistė Gulla

Abstract readReview

PubMed Full text at PMC Publisher

In one paragraph

Review in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Akvilė ZajanckauskaiteDepartment of Human and Medical Genetics, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania.

Miah LingelbachSchool of Osteopathic Medicine, A.T. Still University, Mesa, AZ 85206, USA.

Dovilė JuozapaitėVilnius Santaros Klinikos Biobank, Vilnius University Hospital Santaros Klinikos, 08661 Vilnius, Lithuania.

Algirdas UtkusDepartment of Human and Medical Genetics, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania.

Greta RukšnaitytėDroplet Genomics, 10223 Vilnius, Lithuania.

Goda JonuškienėClinic of Hematology and Oncology, Institute of Clinical Medicine, Faculty of Medicine, 01513 Vilnius, Lithuania.

Aistė GullaInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is associated with high morbidity and mortality. One of the main challenges in the management of HCC is late clinical presentation and thus diagnosis of the disease, which results in poor survival. The pathogenesis of HCC is complex and involves chronic liver injury and genetic alterations. Diagnosis of HCC can be made either by biopsy or imaging; however, conventional tissue-based biopsy methods and serological biomarkers such as AFP have limited clinical applications. While hepatocellular carcinoma is associated with a range of molecular alterations, including the activation of oncogenic signaling pathways, such as Wnt-TGFβ, PI3K-AKT-mTOR, RAS-MAPK, MET, IGF, and Wnt-β-catenin and

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorHumansMicrofluidic Analytical TechniquesMicrofluidicsSingle-Cell AnalysisBiomarkers, Tumorhepatocellular carcinomaheterogeneity cancer liver sequencingsingle-cell analysis

Identifiers

PMID39457366

DOI10.3390/genes15101242

PMCPMC11508129

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.